Medical device makers Boston Scientific Corp. and Edwards Lifesciences Corp. reached a global settlement to resolve their patent disputes in all the countries.
Under the agreement, Irvine, Calif.-based Edwards Lifesciences made a one-time payment of $180 million to Marlborough, Mass.-based Boston Scientific. The companies added that rest of the terms of the agreement were confidential.
According to a Jan. 15 news release, the agreement will also lift any injunctions sought as part of the litigation, and the parties will not owe any royalties to each other.
The disputes were related to patents on products such as transcatheter aortic valves, certain mitral valve repair devices and left atrial appendage closure devices. The transcatheter aortic valve is a device used to replace the dysfunctional valve between the main pumping chamber of the heart and the main artery of the body.
Transcatheter mitral valve repair devices are used to treat mitral regurgitation, which is a leakage of blood backward through the mitral valve each time one of the heart's chamber closes. The left atrial appendage closure device is used in a procedure that closes off the opening of the left atrial appendage, a small pouch found in the top left of the heart.
Boston Scientific and Edwards Lifesciences were fighting multiple lawsuits in several countries including the U.K., Germany and the U.S., with Boston Scientific receiving several favorable rulings. A German court had ruled in October 2018 that Boston Scientific had the right to block the sales of Edwards' valve in Germany as part of preliminary injunction proceedings.